RT Journal Article
SR Electronic
T1 A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.26.20040709
DO 10.1101/2020.03.26.20040709
A1 Fanfan Zeng
A1 Chan Dai
A1 Pengcheng Cai
A1 Jinbiao Wang
A1 Lei Xu
A1 Jianyu Li
A1 Guoyun Hu
A1 Lin Wang
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.26.20040709.abstract
AB Objective To compare the difference of SARS-CoV-2 IgG antibody between male and female COVID-19 patients and figure out a possible explanation for different outcome between male and female patients.Methods A total number of 331 patients confirmed SARS-CoV-2 infection were enrolled. The plasma of these patients were collected during hospitalization and were detected for SARS-CoV-2 IgG antibody. Afterwards, the difference of IgG antibody between male and female patients was analyzed.Results The level of IgG antibody in mild, general and recovering patients showed on difference between male and female. In severe status, the average IgG antibody level in female patients tended to be higher than that of in male patients. Compared with male patients, most of the female patients generated a relatively high level of SARS-CoV-2 IgG antibody in severe status. In addition, the generation of IgG antibody in female tended to be stronger than male patients in disease early phase.Conclusions The inconsistent of SARS-CoV-2 IgG antibody generation in male and female patients may account for the different outcome of COVID-19 between gender.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding support in this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from the author upon request.